Results 21 to 30 of about 31,541 (206)

Chemical and Toxicological Analysis of Antiretroviral Drugs

Разработка и регистрация лекарственных средств, 2019
Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov, M. V. Belova, D. D. Stolyarova, I. E. Shohin, D. S. Bogdanova, O. A. Miskiv, Yu. V. Medvedev, I. M. Korenskaya   +7 more
doaj   +1 more source

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis [PDF]

, 2009
Background: The OK04 trial has shown that 48 weeks of lopinavir-ritonavir monotherapy with reintroduction of nucleosides as needed was noninferior to continuation of triple therapy with 2 nucleosides and lopinavir-ritonavir in patients with prior stable ...
Pulido Ortega, Federico, Rubio García, Rafael, Arribas, Jose R.   +2 more
core   +1 more source

Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients

Southern African Journal of Infectious Diseases, 2020
Background: Currently there is no proven medical treatment for COVID-19. We aimed to determine the factors affecting mortality and changes in clinical and laboratory findings in patients with severe COVID-19 pneumonia treated with lopinavir/ritonavir ...
Omer Ayten, Bengu Saylan
doaj   +1 more source

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Frontiers in Medicine, 2021
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID ...
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Marialaura Bonaccio, Raffaele Bruno, Raffaele Bruno, Roberto Cauda, Roberto Cauda, Alessandro Gialluisi, Giovanni Guaraldi, Lorenzo Menicanti, Marco Mennuni, Ilaria My, Agostino Parruti, Giuseppe Patti, Stefano Perlini, Stefano Perlini, Francesca Santilli, Carlo Signorelli, Giulio G. Stefanini, Alessandra Vergori, Walter Ageno, Luca Aiello, Piergiuseppe Agostoni, Piergiuseppe Agostoni, Samir Al Moghazi, Rosa Arboretti, Filippo Aucella, Greta Barbieri, Martina Barchitta, Alessandro Bartoloni, Carolina Bologna, Paolo Bonfanti, Paolo Bonfanti, Lucia Caiano, Laura Carrozzi, Antonio Cascio, Giacomo Castiglione, Mauro Chiarito, Arturo Ciccullo, Antonella Cingolani, Antonella Cingolani, Francesco Cipollone, Claudia Colomba, Crizia Colombo, Francesco Crosta, Giovanni Dalena, Chiara Dal Pra, Gian Battista Danzi, Damiano D'Ardes, Katleen de Gaetano Donati, Francesco Di Gennaro, Giuseppe Di Tano, Gianpiero D'Offizi, Tommaso Filippini, Francesco Maria Fusco, Carlo Gaudiosi, Ivan Gentile, Giancarlo Gini, Elvira Grandone, Gabriella Guarnieri, Gennaro L. F. Lamanna, Giovanni Larizza, Armando Leone, Veronica Lio, Angela Raffaella Losito, Gloria Maccagni, Stefano Maitan, Sandro Mancarella, Rosa Manuele, Massimo Mapelli, Massimo Mapelli, Riccardo Maragna, Riccardo Maragna, Lorenzo Marra, Giulio Maresca, Claudia Marotta, Franco Mastroianni, Maria Mazzitelli, Alessandro Mengozzi, Francesco Menichetti, Jovana Milic, Filippo Minutolo, Beatrice Molena, R. Mussinelli, Cristina Mussini, Maria Musso, Anna Odone, Marco Olivieri, Emanuela Pasi, Annalisa Perroni, Francesco Petri, Biagio Pinchera, Carlo A. Pivato, Venerino Poletti, Claudia Ravaglia, Marco Rossato, Marianna Rossi, Anna Sabena, Francesco Salinaro, Vincenzo Sangiovanni, Carlo Sanrocco, Laura Scorzolini, Raffaella Sgariglia, Paola Giustina Simeone, Michele Spinicci, Enrico Maria Trecarichi, Giovanni Veronesi, Roberto Vettor, Andrea Vianello, Marco Vinceti, Marco Vinceti, Elena Visconti, Laura Vocciante, Raffaele De Caterina, Licia Iacoviello, Licia Iacoviello, The COVID-19 RISK and Treatments (CORIST) Collaboration   +119 more
doaj   +1 more source

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? [PDF]

, 2011
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can ...
Braun, Patrick, Ehret Robert, Naeth, Gudrun, Frank Wiesmann, Tappe André, Tappe, André, Rolf Kaiser, Martin Stürmer, Hauke Walter, Jan Vachta, Walter, Hauke, André Tappe, Ehret, Robert, Stürmer Martin, Thomas Berg, Kaiser Rolf, Robert Ehret, Berg Thomas, Naeth Gudrun, Knechten Heribert, Gudrun Naeth, Patrick Braun, Knechten, Heribert, Stürmer, Martin, Wiesmann, Frank, Vachta, Jan, Heribert Knechten, Kaiser, Rolf, Berg, Thomas, Walter Hauke, Martin Däumer, Braun Patrick, Däumer Martin, Wiesmann Frank, Vachta Jan, Däumer, Martin   +35 more
core   +1 more source

Sex differences in hypertension among people living with HIV after initiation of antiretroviral therapy

Frontiers in Cardiovascular Medicine, 2022
BackgroundHypertension is common in people living with HIV (PLWH) on antiretroviral therapy (ART). In the general population and in experimental animal models, the incidence of hypertension is greater in males than in females, especially during the ...
Sepiso K. Masenga, Sepiso K. Masenga, Joreen P. Povia, Katongo H. Mutengo, Benson M. Hamooya, Selestine Nzala, Douglas C. Heimburger, Douglas C. Heimburger, Sody M. Munsaka, Fernando Elijovich, Kaushik P. Patel, Annet Kirabo   +11 more
doaj   +1 more source

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy [PDF]

, 2015
Objectives: To assess the influence of body weight and missed doses on lopinavir pharmacokinetics with standard and increased doses of lopinavir/ritonavir melt extrusion tablets during late pregnancy.
Buranabanjasatean, S., Lallemant, Marc, Cressey, T. R., Sabsanong, P., Best, B. M., Jourdain, Gonzague, Capparelli, E. V., Rawangban, B., Urien, S., Limtrakul, A., Treluyer, J. M., Stek, A., Mirochnick, M.   +12 more
core   +3 more sources

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study

AIDS Research and Therapy, 2012
Background Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia.
Sinxadi Phumla Z, McIlleron Helen M, Dave Joel A, Smith Peter J, Levitt Naomi S, Maartens Gary   +5 more
doaj   +1 more source

Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review

Borneo Journal of Pharmacy, 2020
At the end of December 2019, a novel coronavirus was identified which caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a disease known as coronavirus disease 2019 (COVID-19).
Mohammad Mukim, Atul Kabra, Siwani Devi, Mohit Chaturvedi, Rakesh Patel   +4 more
doaj   +1 more source

COVID‐19: A review of therapeutics under investigation

Journal of the American College of Emergency Physicians Open, 2020
The COVID‐19 outbreak has disrupted global health care networks and caused thousands of deaths and an international economic downturn. Multiple drugs are being used on patients with COVID‐19 based on theoretical and in vitro therapeutic targets.
James C. Crosby, Matthew A. Heimann, Samuel L. Burleson, Brendan C. Anzalone, Jonathan F. Swanson, Douglas W. Wallace, Christopher J. Greene   +6 more
doaj   +1 more source